We’re a father-and-son team dedicated to helping individual investors achieve financial independence through strategic dividend investing. With years of combined experience and a deep understanding of the markets, we’ve developed a straightforward yet powerful method that empowers investors like you to take control of your financial future, create a massive dividend snowball, and retire happy and free. At The Dividend Freedom Tribe, we don’t serve institutional clients or cater to Wall Street’s elite. Inste ...

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its ...

INDIA - 2025/01/28: In this photo illustration, a Merck logo is seen displayed on a smartphone with ... [+] an Artificial Intelligence (text) in the background. (Photo Illustration by Avishek Das/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $15.6 billion and adjusted earnings of $1.72 per share, compared to the consensus estimates ...

This article might be the most instructive "case in point" about how I think as an investor. And hopefully it will reinforce or introduce to investors, as the case may be, why I am so adamant about what I call the "HOW" step of my investment process. ThatI'm Rob Isbitts, founder of Sungarden Investment Publishing. I run the new investing group Sungarden YARP Portfolio, a community dedicated to navigating the modern investment climate with humility, discipline, and a non-traditional approach to income invest ...

Shares of Merck (MRK -9.51%) were trading lower on Tuesday. The company's stock had lost 10.1% as of 2 p.m. ET, but was down as much as 12.5% earlier in the day. The drop comes as the S&P 500 gained 0.5% and the Nasdaq Composite gained 1.1% on the day.Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly beat Wall Street's revenue targets, weak guidance for 2025 disappointed investors.The numbersFor Q4 2024, Merck reported global sales of ...

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .I'm not breaking any news when I say that healthcare costs are becoming an issue. I believe we all have felt this through rising healthcare premiums and other ways.Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABBV either through stock ownership, op ...

Merck (MRK) reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents. This significant upside was on account of a one-time charge incurred by the company in the year-ago quarter for a collaboration with Daiichi Sankyo.See the Zacks Earnings Calendar to stay ahead of market-making news.Revenues rose 7% year over year (9% excluding Fx) to $15.62 billion. Sales also beat the Zac ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

For the quarter ended December 2024, Merck (MRK) reported revenue of $15.62 billion, up 6.8% over the same period last year. EPS came in at $1.72, compared to $0.03 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $15.55 billion, representing a surprise of +0.45%. The company delivered an EPS surprise of +1.78%, with the consensus EPS estimate being $1.69.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they c ...

Key TakeawaysMerck shares fell sharply Tuesday morning after the drugmaker's profits and 2025 outlook fell short of estimates.Revenue and adjusted earnings, however, managed to top expectations.Sales of a few Merck drugs were hit by lower international demand and lower pricing in the U.S., the company said. Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue that topped expectations. Merck (MRK) reported $15.62 billion in revenue for the quarter, up 7% y ...